BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan
· Delayed Price · Currency is TWD 31.70
+0.05 (0.16%)
Apr 2, 2025, 1:30 PM CST
BioGend Therapeutics Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Cash & Equivalents | 219.02 | 330.51 | 163.64 | 136.32 | 120.04 | Upgrade
|
| Short-Term Investments | 400 | 393.76 | 329.76 | 552.96 | 392.99 | Upgrade
|
| Cash & Short-Term Investments | 619.02 | 724.27 | 493.4 | 689.28 | 513.03 | Upgrade
|
| Cash Growth | -14.53% | 46.79% | -28.42% | 34.36% | 38.74% | Upgrade
|
| Accounts Receivable | 47.36 | 26.69 | 11.27 | 5.05 | 0.28 | Upgrade
|
| Other Receivables | 33.37 | 30.67 | 28.25 | 23.61 | 21.62 | Upgrade
|
| Receivables | 80.72 | 57.36 | 39.52 | 28.66 | 21.89 | Upgrade
|
| Inventory | 15.96 | 16.55 | 4.9 | 9.03 | 10.41 | Upgrade
|
| Prepaid Expenses | 2 | 3 | 4.07 | 7.57 | 1.42 | Upgrade
|
| Total Current Assets | 717.7 | 801.18 | 541.89 | 734.54 | 546.75 | Upgrade
|
| Property, Plant & Equipment | 49.57 | 56.2 | 34.01 | 8.89 | 5.94 | Upgrade
|
| Long-Term Investments | 8.33 | 20.34 | 10 | - | 69.43 | Upgrade
|
| Goodwill | 17.09 | 17.09 | 17.09 | 17.09 | - | Upgrade
|
| Other Intangible Assets | 114.07 | 151.04 | 210.95 | 261.92 | 102.29 | Upgrade
|
| Other Long-Term Assets | 5.94 | 4.64 | 7.89 | 1.42 | 0.94 | Upgrade
|
| Total Assets | 912.7 | 1,050 | 821.82 | 1,024 | 725.34 | Upgrade
|
| Accounts Payable | 4.22 | 2.16 | 2.08 | 0.49 | 1.36 | Upgrade
|
| Accrued Expenses | 20.61 | 16.57 | 17.22 | 14.39 | 14.19 | Upgrade
|
| Current Portion of Leases | 3.59 | 3.65 | 3.49 | 3.94 | - | Upgrade
|
| Other Current Liabilities | 4.81 | 23.87 | 9.07 | 6.3 | 2.72 | Upgrade
|
| Total Current Liabilities | 33.23 | 46.25 | 31.86 | 25.13 | 18.27 | Upgrade
|
| Long-Term Leases | 5.84 | 9.44 | 12.28 | 0.48 | - | Upgrade
|
| Long-Term Unearned Revenue | - | 2.5 | 2.5 | 2.5 | 2.5 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 27.13 | 35.52 | 43.92 | 52.31 | - | Upgrade
|
| Total Liabilities | 66.19 | 93.71 | 90.56 | 80.42 | 20.77 | Upgrade
|
| Common Stock | 1,243 | 1,231 | 1,031 | 1,031 | 920 | Upgrade
|
| Additional Paid-In Capital | - | - | - | 212.85 | 160.9 | Upgrade
|
| Retained Earnings | -398.32 | -281.85 | -325.52 | -353.91 | -376.33 | Upgrade
|
| Comprehensive Income & Other | -26.58 | -7.96 | -2.38 | -2.16 | - | Upgrade
|
| Total Common Equity | 817.67 | 940.96 | 702.86 | 887.54 | 704.57 | Upgrade
|
| Minority Interest | 28.84 | 15.81 | 28.4 | 55.91 | - | Upgrade
|
| Shareholders' Equity | 846.51 | 956.77 | 731.27 | 943.45 | 704.57 | Upgrade
|
| Total Liabilities & Equity | 912.7 | 1,050 | 821.82 | 1,024 | 725.34 | Upgrade
|
| Total Debt | 9.43 | 13.09 | 15.77 | 4.42 | - | Upgrade
|
| Net Cash (Debt) | 609.59 | 711.18 | 477.64 | 684.86 | 513.03 | Upgrade
|
| Net Cash Growth | -14.28% | 48.90% | -30.26% | 33.49% | 38.74% | Upgrade
|
| Net Cash Per Share | 4.95 | 5.91 | 4.63 | 6.76 | 5.87 | Upgrade
|
| Filing Date Shares Outstanding | 124.26 | 123.08 | 103.08 | 103.08 | 92 | Upgrade
|
| Total Common Shares Outstanding | 124.26 | 123.08 | 103.08 | 103.08 | 92 | Upgrade
|
| Working Capital | 684.47 | 754.93 | 510.03 | 709.42 | 528.47 | Upgrade
|
| Book Value Per Share | 6.58 | 7.65 | 6.82 | 8.61 | 7.66 | Upgrade
|
| Tangible Book Value | 686.51 | 772.83 | 474.82 | 608.52 | 602.28 | Upgrade
|
| Tangible Book Value Per Share | 5.52 | 6.28 | 4.61 | 5.90 | 6.55 | Upgrade
|
| Machinery | 31.6 | 31.19 | 24.66 | 24.55 | 23.87 | Upgrade
|
| Construction In Progress | - | 37.57 | 14.91 | - | - | Upgrade
|
| Leasehold Improvements | 38.15 | 0.34 | 0.34 | 0.34 | 3.03 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.